NCT06952231View on ClinicalTrials.gov

Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 21, 2024

Primary Completion Date

December 10, 2024

Study Completion Date

January 5, 2025

Conditions
Diabetes Mellitus
Interventions
DRUG

Sitagliptin + Metformin

Self administration of Sitagliptin (as phosphate monohydrate) 50 mg twice daily plus metformin HCl 1000 mg twice daily

DRUG

Empagliflozin + Metformin

Self administration of Empagliflozin 12.5 mg twice daily plus metformin HCl 1000 mg twice daily.

Trial Locations (1)

Unknown

The University of Lahore, Lahore

All Listed Sponsors
collaborator

University of Lahore Hospital (ULH)

NETWORK

lead

University of Lahore

OTHER

NCT06952231 - Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter